Cargando…
Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Blackwell Publishing Ltd
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592347/ https://www.ncbi.nlm.nih.gov/pubmed/19183322 http://dx.doi.org/10.1111/j.1464-5491.2008.02484.x |
| _version_ | 1782161544676638720 |
|---|---|
| author | Courrèges, J-P Vilsbøll, T Zdravkovic, M Le-Thi, T Krarup, T Schmitz, O Verhoeven, R Bugáñová, I Madsbad, S |
| author_facet | Courrèges, J-P Vilsbøll, T Zdravkovic, M Le-Thi, T Krarup, T Schmitz, O Verhoeven, R Bugáñová, I Madsbad, S |
| author_sort | Courrèges, J-P |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2592347 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2008 |
| publisher | Blackwell Publishing Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-25923472008-12-04 Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes Courrèges, J-P Vilsbøll, T Zdravkovic, M Le-Thi, T Krarup, T Schmitz, O Verhoeven, R Bugáñová, I Madsbad, S Diabet Med Letters Blackwell Publishing Ltd 2008-09 /pmc/articles/PMC2592347/ /pubmed/19183322 http://dx.doi.org/10.1111/j.1464-5491.2008.02484.x Text en © 2008 The Authors. Journal compilation © 2008 Diabetes UK |
| spellingShingle | Letters Courrèges, J-P Vilsbøll, T Zdravkovic, M Le-Thi, T Krarup, T Schmitz, O Verhoeven, R Bugáñová, I Madsbad, S Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes |
| title | Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes |
| title_full | Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes |
| title_fullStr | Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes |
| title_full_unstemmed | Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes |
| title_short | Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes |
| title_sort | beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes |
| topic | Letters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592347/ https://www.ncbi.nlm.nih.gov/pubmed/19183322 http://dx.doi.org/10.1111/j.1464-5491.2008.02484.x |
| work_keys_str_mv | AT courregesjp beneficialeffectsofoncedailyliraglutideahumanglucagonlikepeptide1analogueoncardiovascularriskbiomarkersinpatientswithtype2diabetes AT vilsbøllt beneficialeffectsofoncedailyliraglutideahumanglucagonlikepeptide1analogueoncardiovascularriskbiomarkersinpatientswithtype2diabetes AT zdravkovicm beneficialeffectsofoncedailyliraglutideahumanglucagonlikepeptide1analogueoncardiovascularriskbiomarkersinpatientswithtype2diabetes AT lethit beneficialeffectsofoncedailyliraglutideahumanglucagonlikepeptide1analogueoncardiovascularriskbiomarkersinpatientswithtype2diabetes AT krarupt beneficialeffectsofoncedailyliraglutideahumanglucagonlikepeptide1analogueoncardiovascularriskbiomarkersinpatientswithtype2diabetes AT schmitzo beneficialeffectsofoncedailyliraglutideahumanglucagonlikepeptide1analogueoncardiovascularriskbiomarkersinpatientswithtype2diabetes AT verhoevenr beneficialeffectsofoncedailyliraglutideahumanglucagonlikepeptide1analogueoncardiovascularriskbiomarkersinpatientswithtype2diabetes AT buganovai beneficialeffectsofoncedailyliraglutideahumanglucagonlikepeptide1analogueoncardiovascularriskbiomarkersinpatientswithtype2diabetes AT madsbads beneficialeffectsofoncedailyliraglutideahumanglucagonlikepeptide1analogueoncardiovascularriskbiomarkersinpatientswithtype2diabetes |